Evidence map›Paper›PMID 26047060›Full record

ReviewCancer biology & therapy2015

Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature.

Elisabetta Di Liso, Natale Pennelli, Gigliola Lodovichetti, Cristina Ghiotto, Angelo Paolo Dei Tos, PierFranco Conte, Laura Bonanno

Open access · bronzeAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer biology & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Potential role ofFrontiers in pediatrics · 2022
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Elisabetta Di Lisoa Medical Oncology 2 ; Istituto Oncologico Veneto IRCCS ; Padova , Italy.
Natale Pennelli
Gigliola Lodovichetti
Cristina Ghiotto
Angelo Paolo Dei Tos
PierFranco Conte
Laura Bonanno
Istituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Padua · ITCa' Foncello Hospital · ITIstituto Oncologico Veneto · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interdigitating dendritic cell sarcoma is an extremely rare tumor. The diagnosis is difficult and is based on clinical, pathological and immunohistochemical evaluation. Differential diagnosis includes melanoma, mesenchymal and hematological malignancies. The mainstay of treatment is surgery for limited disease and different chemotherapy combinations have been tested for advanced disease. No evidence from prospective trials is currently available. We report the case of a 59 year-old male patient who experienced axillary lymphadenopathy with initial diagnosis of large-cell lung cancer on tumor biopsy. He underwent surgical resection with radical intent. Pathological diagnosis of interdigitating dendritic cell sarcoma was obtained on surgical samples. Nine months after radical surgery, he experienced systemic recurrence of disease and underwent chemotherapy with epirubicin and ifosfamide for 4 courses. During chemotherapy, he developed brain disease progression and underwent whole-brain radiotherapy. Systemic progression was then observed and molecular characterization was performed. B-RAF evaluation resulted positive for V600E mutation and the patient was treated with Vemurafenib according to molecular findings. He thus obtained initial clinical benefit but eventually died of brain hemorrhage. In conclusion, we report a case of B-RAF mutation detected in an interdigitating dendritic cell sarcoma patient treated with targeted therapy. B-RAF pathway could have a role in pathogenesis and evolution of this rare disease and could open new perspectives of treatment.

Indexed as

MutationAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsDendritic Cell Sarcoma, InterdigitatingEpirubicinHumansIfosfamideIndolesMaleMiddle AgedMolecular Targeted TherapyProto-Oncogene Proteins B-rafSulfonamidesVemurafenibBRAF protein, humanEpirubicinIfosfamideIndolesProto-Oncogene Proteins B-rafSulfonamidesVemurafenib18FDG- PET-CT, 18fluorodeoxyglucose-positron emission tomography-computed tomographyALK, anaplastic lymphoma kinaseATP, adenosine triphosphateBCL2, B-cell lymphoma 2B-RAFCD, cluster of differentiationCTCAE, common terminology criteria for adverse eventsCT, computed tomographydifferential diagnosisECG, electrocardiogramECOG, eastern cooperative oncology groupEMA, ephitelial membrane antigenH3Ac, acetylated histone H3HLA, human leukocyte antigenIgH, heavy immunoglobulinIg, immunoglobulininterdigitating dendritic cell sarcomaMHC, Major Histocompatibility ComplexMRI, magnetic resonance imagingNSE, neuron specific enolasePS, performance statusQTc, corrected QT intervalSUV, standardized uptake valueTCR, t cell receptorTIM, T cell immunoglobulin mucinVemurafenibWHO, world health organization

Identifiers

PMID26047060
PMCPMC4623311
OpenAlexW1752014943

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.